Fire service offers free visits for dementia care
The initiative, run by Northamptonshire Fire and Rescue Service, offers tailored advice and support aimed at reducing the risk of fire in the homes of people living with the condition.
The service said the symptoms of dementia, such as memory loss or confusion, can increase the risk of accidents involving cookers or electrical appliances.
"Home fire safety visits can be tailored to help people who have dementia, addressing individual concerns and challenges they may face in the home," said Tina Collett from the service's home fire safety team.
Crews can provide advice including fitting shut-off devices that stop the gas supply if a cooker is left on, or installing gas taps that can be turned off entirely to prevent unsupervised use.
Ms Collett added: "We know how concerning it can be to live independently with dementia, especially for [other] family members.
"Our staff will be on hand to offer friendly advice, and even fit free smoke alarms for people who are vulnerable."
Individuals and agencies can book visits online while the service has a fire safety checker on its website.
Follow Northamptonshire news on BBC Sounds, Facebook, Instagram and X.
Firefighters tackle blaze at Althorp farmhouse
Industrial estate reopens after warehouse fire
Northamptonshire Fire and Rescue Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
These medications could save thousands of lives – but doctors aren't prescribing them
In 2021, varenicline, the most effective single drug for quitting smoking, was withdrawn from the market in the UK because impurities were found at greater levels than is considered safe. Rapidly, varenicline (then sold under its brand names, Champix and Chantix) became unavailable. This was a disaster for public health. Research from University College London estimated that varenicline being unavailable resulted in about 1,890 more avoidable deaths each year because fewer people were successfully quitting smoking. But there was hope. Cytisine (also known as cytisinicline), a naturally occurring plant-based product that had been used for decades in Eastern Europe, and more recently to great effect elsewhere in the world, was licensed in the UK and made available from January 2024. Even so, there was an extended period when neither were available to people trying to quit smoking in the UK (and in other countries, too). But in the UK at least, things were looking up. Based on a limited but growing body of evidence, cytisine probably works as well as varenicline at helping people quit smoking, and it may be better tolerated with fewer side effects. It may also appeal to more smokers who may want to use a natural product rather than a drug designed in a lab. So, with varenicline withdrawn and a similarly effective treatment available, we should have seen lives saved as people who would have taken varenicline were encouraged to try cytisine instead. Why isn't anyone prescribing it? This didn't happen. Cytisine – despite now being licensed and available in the UK – is still shockingly underused. Since January 2024, only 0.2% of people trying to quit smoking have used it (the same proportion that used it in 2018, when it wasn't even officially available in the UK). Official NHS data from people accessing stop-smoking services in England confirm that only 0.7% were prescribed cytisine in 2024. So why is this? High-profile trials continue to show cytisine's effectiveness for quitting smoking (and even for quitting vaping). Maybe cytisine's relatively complex dosing schedule puts people off. Cytisine starts with six pills a day (one every two hours) and gradually tapers off over a few weeks: more confusing and less convenient than one-a-day varenicline. Another possibility is that the public's attention has shifted. With so much focus in recent years on vaping as a smoking cessation aid, prescription drugs for smoking cessation may have fallen off the radar. It could also be that GPs are reluctant to prescribe cytisine because of its cost and the assumption that local authorities should pay for it, not primary care. While it was once hoped that due to its low-cost availability in Eastern Europe, it would become the 'aspirin of smoking cessation drugs', the licensed product in the UK is now as or more expensive than other drugs. But the simplest explanation is probably the most accurate: not enough people know about cytisine. People who smoke, GPs, pharmacists and even stop-smoking services may not know it's an option. And if no one is talking about it, no one is prescribing it. And even if they do know about it, there may be a lack of confidence in using or prescribing it because it is a new drug. That's a problem. The UK government has made the shift from treating illness to preventing it a central part of its health strategy. Smoking remains the leading cause of preventable death in the country and the world. If we're serious about prevention, then effective smoking cessation support must be top of the agenda. Now, varenicline is available again (without its brand names and reformulated to remove the impurities). This is welcome news, but only 1.1% of past-year smokers reported using varenicline. That's only a quarter of the number from before its withdrawal. This raises an important question: should we return to prescribing varenicline by default, or is it time to consider cytisine as a first-line treatment? Researchers are continuing to learn more about cytisine, but as the evidence in favour of cytisine grows, maybe it needs a PR campaign for both prescribers and people who smoke. None of this is to say that cytisine is a miracle cure, or that it will work for everyone. But that's true of every way to help people quit smoking. Quitting smoking is hard, and people trying to quit need more options, not fewer, and those options need to be visible and accessible. Jonathan Livingstone-Banks is a Lecturer & Senior Researcher in Evidence-Based Healthcare at the University of Oxford. Dimitra Kale is a Senior Research Fellow in Health Psychology at UCL. Lion Shahab is a Professor in Health Psychology at UCL. This article is republished from The Conversation under a Creative Commons license. Read the original article.
Yahoo
2 hours ago
- Yahoo
The disease which takes 3.5 years to diagnose after symptoms start
A disease that affects almost one million people in the UK takes around 3.5 years to diagnose, researchers have found. Dementia sufferers have to wait a lengthy time from the onset of symptoms to an official diagnosis. And some people with early-onset dementia have an even longer wait of just over four years. A new study by UCL researchers is the first systematic review and meta-analysis of global evidence examining time to diagnosis in dementia. READ MORE: Learner drivers 'struggling to pass' as three Midland test centres among the UK's toughest The researchers reviewed data from 13 previously published studies which took place in Europe, US, Australia and China, reporting data on 30,257 participants. The study, published in the International Journal of Geriatric Psychiatry, investigated the average interval between symptom onset rated by patients or family carers using interviews or medical records to the final diagnosis of dementia. Lead author, Dr Vasiliki Orgeta, said: "Timely diagnosis of dementia remains a major global challenge, shaped by a complex set of factors, and specific healthcare strategies are urgently needed to improve it. "Other studies estimate that only 50-65% of cases are ever diagnosed in high-income countries, with many countries having even lower diagnostic rates. 'Timely diagnosis can improve access to treatments and for some people prolong the time living with mild dementia before symptoms worsen.' In a pooled meta-analysis of 10 of the included studies, the researchers found that it typically takes 3.5 years from the first alert of symptoms to a patient receiving a diagnosis of dementia, or 4.1 years for those with early-onset dementia, with some groups more likely to experience longer delays, a spokesperson for UCL said. They found that younger age at onset and having frontotemporal dementia were both linked to longer time to diagnosis. While data on racial disparities was limited, one of the studies reviewed found that black patients tended to experience a longer delay before diagnosis. Dr Orgeta said: 'Our work highlights the need for a clear conceptual framework on time to diagnosis in dementia, developed in collaboration with people with dementia, their carers, and supporters.' Dr Phuong Leung (UCL Division of Psychiatry) said: 'Symptoms of dementia are often mistaken for normal ageing, while fear, stigma, and low public awareness can discourage people from seeking help.' Professor Rafael Del-Pino-Casado, of the University of Jaén, Spain, said: 'Within healthcare systems, inconsistent referral pathways, limited access to specialists, and under-resourced memory clinics can create further delays. For some, language differences or a lack of culturally appropriate assessment tools can make access to timely diagnosis even harder.' Dr Orgeta added: 'To speed up dementia diagnosis, we need action on multiple fronts. Public awareness campaigns can help improve understanding of early symptoms and reduce stigma, encouraging people to seek help sooner. "Clinician training is critical to improve early recognition and referral, along with access to early intervention and individualised support so that people with dementia and their families can get the help they need.' The NHS lists common early symptoms of dementia as: memory loss difficulty concentrating finding it hard to carry out familiar daily tasks, such as getting confused over the correct change when shopping struggling to follow a conversation or find the right word being confused about time and place mood changes
Yahoo
2 hours ago
- Yahoo
Nature reserve was once an industrial landscape of smoke and steam
Found on the Hampshire coast, the Lymington Nature Reserve isn't just a haven for wildlife, it's a place with a history vastly different from today's settings. For over 2,000 years, this area was a hub of sea salt production, with the industry flourishing by medieval times and peaking in the early 18th century with 163 active saltpans. The marshes were an industrial landscape of smoke and steam, a far cry from today's tranquil scenes, as can be seen in these pictures by Echo Camera Club member Trevor Parsons. The last saltern closed in 1865, leaving behind unique archaeological remnants that tell a story of human ingenuity and toil. The pivotal shift towards conservation began in the mid-20th century. The Hampshire & Isle of Wight Wildlife Trust started its involvement in 1961, establishing a private nature reserve on 20 acres of salterns. Read more: Bournemouth stonemason stopped bones being stolen from grave Cherished park in Bournemouth shaped by centuries of shared ownership Memories of a much-loved pub that was demolished to make way for flats Mystery of how town's oldest pub got its name The many links between Bournemouth and the Titanic This was swiftly followed by Hampshire County Council's "far-sighted policy" of land acquisition, beginning in 1974, to protect these vital coastal habitats from rapid development. Today, the combined Lymington and Keyhaven Marshes Local Nature Reserve spans more than 1200 hectares, a mosaic of mudflats, salt marshes, shingle banks, and saline lagoons. Its ecological importance is underscored by international designations like Ramsar and Special Protection Area status, vital for countless bird species and rare invertebrates. Yet, this dynamic coastal environment faces ongoing challenges, from coastal squeeze and rising sea levels to declining breeding bird populations, highlighting the continuous need for adaptive management and dedicated stewardship.
